MedTrace Logo

Anecortave Acetate in Patients With Open-angle Glaucoma

NCT00320203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, efficacy, and duration of effect of a single administration of Anecortave Acetate Depot for treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma.

Conditions

  • Open-angle Glaucoma

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 6 mg/mL

Single injection, anterior juxtascleral depot (AJD)

DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Single injection, anterior juxtascleral depot (AJD)

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/mL

Single injection, anterior juxtascleral depot (AJD)

OTHER

Anecortave Acetate Vehicle

Single injection, anterior juxtascleral depot (AJD)

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-01-31
Completion
2008-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320203 on ClinicalTrials.gov